Biphenyl

Biphenyl

SCHEMBL2838517

O=C(O)c1c(F)cc(F)cc1F.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.50
AKR1C1 Q04828 1/20 0.50
DHODH Q02127 7/20 0.45
KMO O15229 1/20 0.44
BCL2L1 Q07817 1/20 0.42
BAD Q92934 1/20 0.42
HNF4A P41235 2/20 0.41
ACMSD Q8TDX5 2/20 0.41
DHFR P00374 1/20 0.41
MCL1 Q07820 1/20 0.41
CDC25B P30305 1/20 0.41
ATM Q13315 1/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL505832 0.89 AKR1C2 (0.61) AKR1C2AKR1C1DHODHKMOHNF4A
SCHEMBL288979 0.87 CES2 (0.46) BCL2L1BADACMSDDHFRKDM4E
SCHEMBL29154306 0.84 CES2 (0.44) BCL2L1BADACMSDDHFRKDM4E
Biphenyl SCHEMBL2831439 0.83 CES2 (0.56) AKR1C2AKR1C1KMOCDC25BATM
SCHEMBL28535010 0.81 AKR1C2 (0.53) AKR1C2AKR1C1DHODHKMOHNF4A
Biphenyl SCHEMBL2835088 0.80 AKR1C2 (0.47) AKR1C2AKR1C1DHODHKMOHNF4A
SCHEMBL28888036 0.77 AKR1C2 (0.45) AKR1C2AKR1C1KMOBCL2L1BAD
SCHEMBL10029672 0.77 AKR1C2 (0.56) AKR1C2AKR1C1DHODHKMOKDM4E
SCHEMBL15845615 0.77 CES2 (0.39) ACMSDDHFRKDM4EMEN1ALDH1A1
SCHEMBL4187835 0.77 ALDH1A1 (0.54) ATMMEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 AKR1C2 1435/4885AKR1C1 1866/4885DHODH 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.